You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

Recent advances in the treatment of multiple myeloma

Desikan, K. Raman MD; Dhodapkar, Madhav V. MD; Munshi, Nikhil C. MD; Barlogie, Bart MD, PhD

Current Opinion in Hematology:
Hematologic malignancies
Abstract

Multiple myeloma, a clonal B-cell malignancy, accounts for 10% of all hematologic cancers. In patients with multiple myeloma, median survival is approximately 30 to 36 months with conventional therapy, but high-dose chemotherapy resulted in better outcomes in a mature randomized trial. Pamidronate and other bisphosponates, used as supportive therapy, effectively reduce the incidence of skeletal events and decrease pain. They also have a role in disease control. Ongoing trials are now addressing such issues as further intensification with tandem transplantations, timing of transplantation, and decrease of malignant cell reinfusion by positive selection. Important laboratory observations have better defined the malignant clone and its interaction with the microenvironment. These observations will be important for the treatment of myeloma in the future.

Author Information

Myeloma and Transplantation Research Center, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA

Correspondence to Bart Barlogie MD, Myeloma and Transplantation Research Center, University of Arkansas for Medical Sciences, 4301 West Markham, Slot 623, Little Rock, AR 72205, USA

© 1999 Lippincott Williams & Wilkins, Inc.